You just read:

RiboMed and Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors

News provided by

RiboMed Biotechnologies, Inc.

Jul 06, 2016, 08:00 ET